earnings
confidence medium
sentiment positive
materiality 0.60
Ekso Bionics expects record Q4 2024 revenue of $5.0-$5.1M, preliminary
EKSO BIONICS HOLDINGS, INC.
2025-FY EPS
reported -$8.43
vs consensus -$0.29
▼ miss
(-2799.9%)
- Q4 2024 revenue estimated at $5.0-5.1M (company record vs $4.8M in Q4 2023).
- Cash $6.5M at Dec 31, 2024, down from $8.6M a year earlier.
- Net cash used in ops Q4 2024 estimated $1.5M, improving from $1.6M year ago.
- CEO highlights initial CMS reimbursement for Ekso Indego Personal device.
- Full Q4 and FY 2024 results expected in first week of March 2025.